Mucopolysaccharidosis type IV (MPS IV), or Morquio syndrome, is an autosomal recessive lysosomal storage disorder primarily characterized by progressive skeletal dysplasia and connective tissue involvement. It is caused by biallelic variants in the GALNS gene (MPS IVA) or, less commonly, in GLB1 (MPS IVB), which impairs the degradation of keratan sulfate and other glycosaminoglycans, with progressive accumulation in cartilage, bone, and other tissues.
Mucopolysaccharidosis type 4
MPS IV comprises two clinically very similar subtypes: MPS IVA, caused by variants in GALNS, and MPS IVB, caused by variants in GLB1. The GALNS gene encodes the enzyme N-acetylgalactosamine-6-sulfatase, which is necessary for the degradation of keratan sulfate and chondroitin-6-sulfate. The GLB1 gene encodes beta-galactosidase, the deficiency of which in MPS IVB prevents the proper degradation of oligosaccharides derived from keratan sulfate.
When these enzymes are deficient, undegraded glycosaminoglycans accumulate within lysosomes and progressively alter the function of cartilage, bone, and connective tissue cells. Therefore, unlike other mucopolysaccharidoses, MPS IV primarily manifests with osteoarticular abnormalities, joint hyperlaxity, and respiratory or cardiac complications, while cognitive development is usually preserved. MPS IVA accounts for more than 95% of cases with Morquio phenotype, and MPS IVB for less than 5%. The disease is inherited in an autosomal recessive manner and its frequency is low, with variable estimates among populations; in some regions, recurrent variants or founder effects have been described.
Symptoms
Symptoms usually appear in early childhood, typically between the first and third year of life in classic forms, although slowly progressive forms may become evident later. The main signs include disproportionate short stature, short trunk, pectus carinatum, kyphosis or scoliosis, genu valgum, hip abnormalities, joint hypermobility, and progressive limitation of mobility. A particularly important complication is odontoid hypoplasia with cervical instability, which can cause spinal cord compression. Mild corneal opacity, hearing loss, heart valve disease, sleep apnea, and respiratory involvement may also occur. An increase in keratan sulfate can be detected in urine.
Disease management
The management of MPS IV is multidisciplinary and aims to preserve mobility, prevent orthopedic and respiratory complications, and improve quality of life. In MPS IVA, enzyme replacement therapy with elosulfase alfa, administered intravenously, is available. This therapy can improve functional capacity and some respiratory parameters, although it does not completely correct established skeletal abnormalities. There is no approved enzyme replacement therapy for MPS IVB. Follow-up should include orthopedic, cardiological, respiratory, ophthalmological, auditory, and dental evaluations. Cervical spine monitoring is essential, especially before anesthesia or surgery, and some patients require cervical stabilization or other orthopedic interventions.
Genes analyzed
Bibliography
Padash S, Obaid H, Henderson RDE, et al. A pictorial review of the radiographic skeletal findings in Morquio syndrome (mucopolysaccharidosis type IV). Pediatr Radiol. 2023.
Cadena Arteaga JA, Lasso Andrade FA, Achicanoy Puchana DM, et al. Mucopolysaccharidosis type IV: report of 5 cases of Morquio Syndrome. Radiol Case Rep. 2021.
